דילוג לתוכן הראשי
xMedica

NCT07353931ClinicalTrials.gov

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in…

שלב 3דרושים 900 משתתפים152 אתרים14 מדינות

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-21; recorded start 2026-02-09
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 347 other studies in this databaseCounted from the lead sponsor named in the record (Eli Lilly and Company)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding13/20

    Double-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 161 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 900 participants (target), run at 152 sites, across 14 countries.

How this score is built
  • Enrolment29/40

    900 participants (target)

  • Site count24/25

    161 sites

  • Country count12/15

    15 countries

  • Planned duration7/10

    Planned over about 27 months

  • Sponsor scale9/10

    Eli Lilly and Company has led 326 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

מצבים רפואיים

  • Osteoarthritis
  • Overweight or Obesity

זכאות

זכאות
מיןהכול
גילאים18 Yearsללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening * Have a stable body weight (less than 5% body weight change) for 90 days prior to screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have an active knee infection * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 3
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהDOUBLE (2)
גיוסדרושים 900 משתתפים

נותן חסות ושותפים

  • Eli Lilly and Company נותן חסות

זרועות והתערבויות

  • Eloralintide (YOA1)EXPERIMENTAL

    Participants will receive eloralintide subcutaneously (SC)

  • Placebo (YOA1)PLACEBO_COMPARATOR

    Participants will receive placebo SC

  • Eloralintide (YOA2)EXPERIMENTAL

    Participants will receive eloralintide SC

  • Placebo (YOA2)PLACEBO_COMPARATOR

    Participants will receive placebo SC

התערבויות

  • תרופה Eloralintide

    Administered SC

  • תרופה Placebo

    Placebo administered SC

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Percent Change from Baseline in Body Weight

    Percent Change from Baseline in Body Weight

    מסגרת זמן Baseline, Week 64

  2. מדד תוצאה ראשוני

    Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

    Change from Baseline in the WOMAC Pain Subscale Score

    מסגרת זמן Baseline, Week 64

  3. מדד תוצאה משני

    Change from Baseline in Systolic Blood Pressure (SBP)

    Change from Baseline in SBP

    מסגרת זמן Baseline, Week 64

  4. מדד תוצאה משני

    Percent Change from Baseline in Triglycerides

    Percent Change in Baseline in Triglycerides

    מסגרת זמן Baseline, Week 64

  5. מדד תוצאה משני

    Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score

    Change from Baseline in SF-36 v2 Score

    מסגרת זמן Baseline, Week 64

  6. מדד תוצאה משני

    Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)

    Percent Change from Baseline in hsCRP

    מסגרת זמן Baseline, Week 64

  7. מדד תוצאה משני

    Change from Baseline in the WOMAC Physical Function Subscale Score

    Change from Baseline in the WOMAC Physical Function Subscale Score

    מסגרת זמן Baseline, Week 40, Week 64

  8. מדד תוצאה משני

    Change from Baseline WOMAC Pain Subscale Score

    Change from Baseline WOMAC Pain Subscale Score

    מסגרת זמן Baseline, Week 40

  9. מדד תוצאה משני

    Change from Baseline in Distance Walked During the 6-Minute Walk Test

    Change from Baseline in Distance Walked During the 6-Minute Walk Test

    מסגרת זמן Baseline, Week 64

  10. מדד תוצאה משני

    Change from Baseline in Body Mass Index (BMI)

    Change from Baseline in BMI

    מסגרת זמן Baseline, Week 64

  11. מדד תוצאה משני

    Change in Medication Use

    Change in Medication Use

    מסגרת זמן Baseline, Week 64

  12. מדד תוצאה משני

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    מסגרת זמן Baseline, Week 64

  13. מדד תוצאה משני

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    מסגרת זמן Baseline, Week 64

  14. מדד תוצאה משני

    Percent Change from Baseline in Fasting Insulin

    Percent Change from Baseline in Fasting Insulin

    מסגרת זמן Baseline, Week 64

  15. מדד תוצאה משני

    Percent Change from Baseline in Total Cholesterol

    Percent Change from Baseline in Total Cholesterol

    מסגרת זמן Baseline, Week 64

  16. מדד תוצאה משני

    Change from Baseline in Waist Circumference

    Change from Baseline in Waist Circumference

    מסגרת זמן Baseline, Week 64

  17. מדד תוצאה משני

    Percent Change from Baseline in Hemoglobin A1c (HbA1c)

    Percent Change from Baseline in HbA1c

    מסגרת זמן Baseline, Week 64

  18. מדד תוצאה משני

    Change from Baseline in WOMAC Stiffness Subscale Score

    Change from Baseline in WOMAC Stiffness Subscale Score

    מסגרת זמן Baseline, Week 64

  19. מדד תוצאה משני

    Change from Baseline in WOMAC Total Score

    Change from Baseline in WOMAC Total Score

    מסגרת זמן Baseline, Week 64

  20. מדד תוצאה משני

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain

    Achievement of Improved Categorical Shift in PGIS - Target Knee Pain

    מסגרת זמן Baseline, Week 64

  21. מדד תוצאה משני

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function

    Achievement of Improved Categorical Shift in PGIS - Target Knee Function

    מסגרת זמן Baseline, Week 64

  22. מדד תוצאה משני

    Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score

    Change from Baseline in API-NRS Score

    מסגרת זמן Baseline, Week 64

  23. מדד תוצאה משני

    Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score

    Change from Baseline in WPI-NRS Score

    מסגרת זמן Baseline, Week 64

  24. מדד תוצאה משני

    Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)

    PK: Cmax, ss

    מסגרת זמן Baseline through Week 64

  25. מדד תוצאה משני

    PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)

    PK: AUC(0-T)ss

    מסגרת זמן Baseline through Week 64

  26. מדד תוצאה משני

    Number of Participants with Allowed Concomitant Pain Medication

    Number of Participants with Allowed Concomitant Pain Medication

    מסגרת זמן Baseline, Week 64

תאריכים

תאריכים
תאריך התחלה9 בפברואר 2026 (בפועל)
סיום ראשוני1 במרץ 2028 (משוער)
סיום1 במאי 2028 (משוער)
פורסם לראשונה21 בינואר 2026 (בפועל)
עודכן לאחרונה8 בספטמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהספטמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

126 אתרים מגייסים

Argentina

Argentina
מתקןעירמדינה או אזורמצב
Centro Privado de Medicina Familiar / Mindout ResearchBuenos Airesטרם מגייס
Centro Médico ArsemaBuenos Airesטרם מגייס
Stat Research S.A.Buenos Airesטרם מגייס
Organizacion Medica de InvestigacionBuenos Airesטרם מגייס
CARDIAMET Investigaciones MédicasBuenos Airesטרם מגייס
Centro de Investigaciones Clínicas BaigorriaGranadero Baigorriaטרם מגייס
INECO Neurociencias OroñoRosarioטרם מגייס
Instituto Especialidades de la Salud RosarioRosarioטרם מגייס
Centro de Investigaciones Médicas TucumanSAN M. de Tucumanטרם מגייס
Medicina ReumatológicaSan Fernandoטרם מגייס
Instituto de Alta Complejidad San IsidroSan Isidroטרם מגייס
Centro Polivalente de Asistencia e Investigacion Clinica - CER San JuanSan Juanטרם מגייס
Centro de Investigaciones ReumatológicasSan Miguel de Tucumánטרם מגייס
Go Centro Medico San NicolásSan Nicolásטרם מגייס

Belgium

Belgium
מתקןעירמדינה או אזורמצב
Antwerp University HospitalEdegemמגייס
Reuma Clinic, Locatie JaarbeurslaanGenkמגייס
UZ GentGhentמגייס
KormontKluisbergenמגייס
UZ LeuvenLeuvenמגייס
MeclinasMechelenמגייס
ZNA Jan PalfijnMerksemטרם מגייס
Medisch Centrum Latem (Hip Clinic) - Algemeen Ziekenhuis Maria Middelares LocationSint-Martens-Latemטרם מגייס

Brazil

Brazil
מתקןעירמדינה או אזורמצב
Centro de Pesquisa Sao LucasCampinasמושהה
IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiroמושהה
CPHosp Medicina, Ensino e Pesquisa (CPQuali)São Pauloמושהה
INTEGRA - Pesquisa Clínica e InfusõesSão Pauloמושהה
CEPIC - Centro Paulista de Investigação ClínicaSão Pauloמושהה
Hospital das Clinicas FMUSPSão Pauloמושהה

Canada

Canada
מתקןעירמדינה או אזורמצב
Apex TrialsGuelphמגייס
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.Québecטרם מגייס
Diex Recherche Inc. Division QuebecQuébecמגייס
Stouffville Medical Research Institute Inc.Stouffvilleמגייס
Maple Leaf ResearchTorontoמגייס
Dr. Anil K. Gupta Medicine Professional CorporationTorontoמגייס
Diex Recherche Inc. Division VictoriavilleVictoriavilleמגייס

China

China
מתקןעירמדינה או אזורמצב
Beijing Ji Shui Tan HospitalBeijingמגייס
The First Afflilated Hospital of Bengbu Medical CollegeBengbuמגייס
Jilin Province People's HospitalChangchunמגייס
The Second Hospital of Jilin UniversityChangchunטרם מגייס
Xiangya Hospital Central South UniversityChangshaמגייס
2nd Affiliated Hospital Chongqing Medical UniversiChongqingמגייס
The Second Affiliated hospital of Zhejiang University school of medicineHangzhouמגייס
The Second People's Hospital of HefeiHefeiמגייס
Jinan Central HospitalJinanמגייס
The First Affiliated Hospital of Henan University of Science &TechnologyLuoyangמגייס
Nanjing First HospitalNanjingמגייס
Zhongda Hospital Southeast UniversityNanjingמגייס
The Second Affiliated Hospital of Nanjing Medical UniversityNanjingמגייס
Jiangsu Province HospitalNanjingמגייס
The first affiliated hospital of Ningbo universityNingboמגייס

102 אתרים נוספים מצוינים ברשומת המרשם.

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 6 באוגוסט 2026

    אתר הוסר

    9 sites removed (152 total)

    161152